Member companies of the UK BioIndustry Association say they want the new Innovative Licensing and Access Pathway (ILAP) to remain open for products in both early and late-stage development, and that “partnership and engagement” among all the stakeholders involved are vital if the new pathway is to be successful.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?